MiMedx Group (NASDAQ:MDXG) Trading Up 3.4% After Insider Buying Activity

MiMedx Group, Inc. (NASDAQ:MDXG - Get Free Report) rose 3.4% during trading on Monday after an insider bought additional shares in the company. The stock traded as high as $6.44 and last traded at $6.54. Approximately 94,907 shares traded hands during mid-day trading, a decline of 86% from the average daily volume of 677,012 shares. The stock had previously closed at $6.32.

Specifically, CEO Joseph H. Capper acquired 200,000 shares of the company's stock in a transaction on Friday, May 2nd. The stock was acquired at an average price of $6.34 per share, for a total transaction of $1,268,000.00. Following the acquisition, the chief executive officer now owns 529,530 shares in the company, valued at $3,357,220.20. This represents a 60.69 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website.

Analyst Upgrades and Downgrades

Several research firms have recently commented on MDXG. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $13.00 target price on shares of MiMedx Group in a research report on Thursday, February 27th. StockNews.com raised MiMedx Group from a "buy" rating to a "strong-buy" rating in a research report on Thursday.

MiMedx Group Price Performance

The firm has a market cap of $977.05 million, a P/E ratio of 12.04 and a beta of 1.85. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53. The firm's 50 day moving average is $7.40 and its 200 day moving average is $8.10.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The company reported $0.06 EPS for the quarter, hitting analysts' consensus estimates of $0.06. The firm had revenue of $88.21 million for the quarter, compared to analysts' expectations of $86.32 million. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. As a group, analysts anticipate that MiMedx Group, Inc. will post 0.3 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. IMG Wealth Management Inc. purchased a new position in MiMedx Group in the 4th quarter worth approximately $28,000. Virtus Fund Advisers LLC bought a new position in shares of MiMedx Group during the fourth quarter valued at $35,000. Van ECK Associates Corp purchased a new stake in shares of MiMedx Group during the fourth quarter valued at $40,000. Tower Research Capital LLC TRC raised its holdings in shares of MiMedx Group by 77.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,501 shares of the company's stock valued at $63,000 after purchasing an additional 2,837 shares during the last quarter. Finally, AlphaQuest LLC purchased a new stake in MiMedx Group during the 4th quarter valued at $88,000. Institutional investors own 79.15% of the company's stock.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.